Spatially resolved transcriptomic profiles reveal unique defining molecular features of infiltrative 5ALA-metabolizing cells associated with glioblastoma recurrence

Andrieux, Geoffroy; Das, Tonmoy; Griffin, Michaela; Straehle, Jakob; Paine, Simon M.L.; Beck, Jürgen; Boerries, Melanie; Heiland, Dieter H.; Smith, Stuart J.; Rahman, Ruman; Chakraborty, Sajib

Abstract

Background

Spatiotemporal heterogeneity originating from genomic and transcriptional variation was found to contribute to subtype switching in isocitrate dehydrogenase-1 wild-type glioblastoma (GBM) prior to and upon recurrence. Fluorescence-guided neurosurgical resection utilizing 5-aminolevulinic acid (5ALA) enables intraoperative visualization of infiltrative tumors outside the magnetic resonance imaging contrast-enhanced regions. The cell population and functional status of tumor responsible for enhancing 5ALA-metabolism to fluorescence-active PpIX remain elusive. The close spatial proximity of 5ALA-metabolizing (5ALA +) cells to residual disease remaining post-surgery renders 5ALA + biology an early a priori proxy of GBM recurrence, which is poorly understood.

Methods
We performed spatially resolved bulk RNA profiling (SPRP) analysis of unsorted Core, Rim, Invasive margin tissue, and FACS-isolated 5ALA + /5ALA − cells from the invasive margin across IDH-wt GBM patients (N = 10) coupled with histological, radiographic, and two-photon excitation fluorescence microscopic analyses. Deconvolution of SPRP followed by functional analyses was performed using CIBEROSRTx and UCell enrichment algorithms, respectively. We further investigated the spatial architecture of 5ALA + enriched regions by analyzing spatial transcriptomics from an independent IDH-wt GBM cohort (N = 16). Lastly, we performed survival analysis using Cox Proportinal-Hazards model on large GBM cohorts.

Results
SPRP analysis integrated with single-cell and spatial transcriptomics uncovered that the GBM molecular subtype heterogeneity is likely to manifest regionally in a cell-type-specific manner. Infiltrative 5ALA + cell population(s) harboring transcriptionally concordant GBM and myeloid cells with mesenchymal subtype, -active wound response, and glycolytic metabolic signature, was shown to reside within the invasive margin spatially distinct from the tumor core. The spatial co-localization of the infiltrating MES GBM and myeloid cells within the 5ALA + region indicates PpIX fluorescence can effectively be utilized to resect the immune reactive zone beyond the tumor core. Finally, 5ALA + gene signatures were associated with poor survival and recurrence in GBM, signifying that the transition from primary to recurrent GBM is not discrete but rather a continuum whereby primary infiltrative 5ALA + remnant tumor cells more closely resemble the eventual recurrent GBM.

Conclusions
Elucidating the unique molecular and cellular features of the 5ALA + population within tumor invasive margin opens up unique possibilities to develop more effective treatments to delay or block GBM recurrence, and warrants commencement of such treatments as early as possible post-surgical resection of the primary neoplasm.

Citation

Andrieux, G., Das, T., Griffin, M., Straehle, J., Paine, S. M., Beck, J., Boerries, M., Heiland, D. H., Smith, S. J., Rahman, R., & Chakraborty, S. (2023). Spatially resolved transcriptomic profiles reveal unique defining molecular features of infiltrative 5ALA-metabolizing cells associated with glioblastoma recurrence. Genome Medicine, 15, Article 48. https://doi.org/10.1186/s13073-023-01207-1

• Journal Article Type: Article
• Acceptance Date: Jun 26, 2023
• Online Publication Date: Jul 11, 2023
• Publication Date: Jul 11, 2023
• Deposit Date: Jul 13, 2023
• Publicly Available Date: Jul 14, 2023
• Journal: Genome Medicine
• Electronic ISSN: 1756-994X
• Publisher: Springer Verlag
• Peer Reviewed: Peer Reviewed
• Volume: 15
• Article Number: 48
• DOI: https://doi.org/10.1186/s13073-023-01207-1
• Keywords: Recurrence, Mesenchymal subtype, 5ALA, Wound response, Spatial transcriptomics, Glycolysis, Myeloid, Glioblastoma
• Public URL: https://nottingham-repository.worktribe.com/output/23000855
• Publisher URL: https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-023-01207-1
• PMID: 37434262